Newton™ Announces VSP Availability for Sequel™ Lenses, Expanding Access to Digital Eye Strain Relief Nationwide

DALLAS, Oct. 15, 2025 /PRNewswire/ -- Newton™ (formerly Neurolens), an innovation company transforming eye care through exceptional patient experiences and outcomes, today announced that Sequel™ lenses are now available through VSP, the nation's largest vision benefits provider. This milestone significantly expands patient access to relief from digital eye strain symptoms affecting up to 75% of device users.²

The Convergence Difference

Most solutions address accommodation—the eye's ability to focus on near objects. Almost none address convergence. And for screen work, convergence demand is significant: eyes must maintain precise alignment for thousands of hours per year. This sustained inward eye movement is the hidden driver of digital eye strain, yet traditional computer glasses leave it completely unsupported.

Sequel's proprietary Convergence Boost™ technology changes this. By supporting both accommodation and convergence simultaneously, Sequel addresses the complete cause of digital eye strain rather than just half the problem.

Sequel is the only lens proven to reduce digital eye strain symptoms by 50%¹, delivering exceptional visual comfort both on-screen and off. The Sequel portfolio—including Sequel 0, 38, 67, and PAL designs—brings this dual-support technology to patients across all prescriptions who struggle with the demands of modern digital lifestyles. 

"VSP members now having access to Sequel represents a major milestone in our mission to bring innovative solutions to patients everywhere," said Davis Corley, CEO of Newton. "Building on the quality and trust we've established with Neurolens, Sequel dramatically improves accessibility and affordability, ensuring these advanced lenses reach the everyday patient in today's digital lifestyle."

Through VSP, Sequel lenses are now accessible to millions of patients nationwide via Founders Optical Lab, Pacific Artisan Labs, Simplify Optics, Independent Vision, and rxotulsa— with more labs coming soon. This represents the next chapter in Newton's commitment to redefining patient comfort and care.

About Newton

Newton is an innovation company transforming eye care through exceptional patient experiences and outcomes. With patented Contoured Prism technology in the Neurolens portfolio and breakthrough Convergence Boost technology in Sequel lenses, Newton empowers eye care providers to deliver measurable relief while elevating the standard of care industry wide.

For more information, visit www.newton.tech

¹ Based on Consumer Product Testing of Sequel 38 and Sequel 67 designs with users experiencing digital eye strain symptoms, n=29 (Sequel 38), n=27 (Sequel 67). Neurolens Data on File: Intelliboost CPT Study 2025 - CVS-Q

² CooperVision (February 2024). "A New Look at Digital Eye Strain". Report of online survey results (2023): N=750, Vision corrected patients. US Adults Ages 18-44 who wear corrective spectacles and/or contact lenses.

SOURCE Newton